New scanning method for osteoporosis - Bone Health

Bone Health

3,309 members1,348 posts

New scanning method for osteoporosis


On BBC Midlands there was a news feature tonight on a new scanning device suitable for measuring bone density without using xrays. It was being tested on cricketers in Worcestershire. It sounds like a great idea as it was fairly portable and reduces exposure to radiation. Perhaps it might mean patients could get tested on a yearly basis?

7 Replies

I didn’t see the report, but it sounds interesting from what you say. Anything to cut radiation exposure should be an improvement.

Sounds promising!

Fran 😊

Definitely one to keep an eye on for future development and roll-out - I'm almost one year in now and have been told that I won't get another scan until the standard 5-year term is up. It would give me some peace of mind to know that an annual scan might be available.

Nanaedake in reply to Heather9

I agree. An annual scan would be helpful.

Even better would be something that measures bone strength rather than bone density, as the two aren't always the same.

Osteoscan UK Ltd

10 August

Faster and more accurate than DEXA! No being strapped down uncomfortably for ages! Quick, on-screen, easy to understand immediate results! Full diagnosis and help/guidance by bone specialist. All in one 30minute appointment.

Osteoscan UK Ltd bone health assessment scan clinic venues, dates and contacts:

Daventry: 20th Sept at Heartlands Physiotherapy Clinic, scan/appointment price £150

Stoney Stratford: 3rd October Action Physiotherapy, £150

London W1: 10th October @The Holistic Women's Clinic, book through their website, £225

Coventry: 12 Oct 2019 & 6 Mar 2020 The Pilates Centre £150

Olney: 17th October Olney Pilates Studio, £150

Solihull: 22nd October Hampton Clinic, £150 (book via The Pilates Centre)

Lincoln: 25th October at Debbie Lynn Pilates Therapy Centre, £150

Stamford: 11th November, The Broad Street Practice £150

Bradford: 22nd November, book via The Pilates Centre £150

Henley-on-Thames: 13th December, at Henley Podiatry and Health Therapies, £150

If you want a scan, please contact the venues as above. A non-refundable (but transferrable) deposit of £25 is due at the time of booking secure your appointment and the balance is due on (or before) a week prior to the scan clinic.

contact or drop us a message for further details or information

Even better, just had this test done after being on Prolia nightmare for 2 years, now on Forteo for 1.5 years with great sucess.

This test allows rapid analysis of bone turnover, just had mine done and it proved out the efficacy of my current modality.

PINP as a biological response marker during teriparatide treatment for osteoporosis

J. H. Krege, N. E. Lane, J. M. Harris, and P. D. Millercorresponding author

Author information Article notes Copyright and License information Disclaimer

This article has been cited by other articles in PMC.

Go to:


Postmenopausal women with severe osteoporosis may require treatment with the bone anabolic drug teriparatide. While changes in bone mineral density (BMD) are one measure of response, BMD changes often require a minimum of one year to observe measureable changes. Biochemical markers of bone turnover change within 1 to 3 months of initiating osteoporosis therapy. Monitoring with a marker such as procollagen type I N propeptide (PINP), an osteoblast-derived protein, during teriparatide treatment may provide clinically useful information for managing patients with osteoporosis. Clinical trials have shown consistent increases in PINP within 3 months of initiating teriparatide, increases that are significantly greater than placebo and significantly different from baseline. Increases in PINP concentrations during teriparatide treatment correlate well with increases in skeletal activity assessed by radioisotope bone scans and quantitative bone histomorphometry parameters. Individuals treated with teriparatide in clinical trials usually experienced an increase in PINP > 10 mcg/L from baseline, while those given placebo usually did not. In the clinical setting, patients experiencing a significant increase in PINP > 10 mcg/L after initiating teriparatide therapy may receive an earlier confirmation of anabolic effect, while those who do not may be assessed for adherence, proper injection technique, or undetected secondary conditions that might mitigate an anabolic response. PINP monitoring may provide information supplemental to BMD monitoring and be a useful aid in managing patients receiving anabolic osteoporosis treatment in the same way that biochemical markers of bone resorption are useful in monitoring antiresorptive therapy. This review examines PINP as a biological response marker during teriparatide treatment for osteoporosis.

Keywords: Anabolics, Biochemical markers of bone turnover, Osteoporosis, PINP, Teriparatide

You may also like...